Surrozen (SRZN) Other Non-Current Assets (2020 - 2026)
Surrozen (SRZN) posted quarterly Other Non-Current Assets of $34000.0 for Q1 2026, down 66.34% year-over-year from $101000.0 in Q1 2025, and down 95.06% quarter-over-quarter from $688000.0 in Q4 2025.
Powered by 
Analysis
Surrozen (SRZN) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Surrozen's Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $34000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 66.34% year-over-year to $34000.0; the TTM figure through Mar 2026 stood at $34000.0 (down 66.34% YoY), while the FY2025 annual figure was $688000.0, changed 0.0% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $34000.0, down from $688000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $904000.0 in Q1 2022, with the low at $34000.0 in Q1 2026.
- The 5-year median for Other Non-Current Assets is $426000.0 (2023), against an average of $522352.9.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets surged 115.62% in 2024, then plunged 90.7% in 2025.
- Surrozen's Other Non-Current Assets stood at $405000.0 in 2022, then decreased by 0.74% to $402000.0 in 2023, then jumped by 71.14% to $688000.0 in 2024, then changed by 0.0% to $688000.0 in 2025, then plunged by 95.06% to $34000.0 in 2026.
- Business Quant data shows SRZN's Other Non-Current Assets at $34000.0 in Q1 2026, $688000.0 in Q4 2025, and $64000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Surrozen | 263.35 Mn | 263.35 Mn | - | 635,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 635,000.00 |
| Mar 31, 2026 | 688,000.00 |
| Dec 31, 2025 | 688,000.00 |
| Sep 30, 2025 | 688,000.00 |
| Jun 30, 2025 | 688,000.00 |
| Mar 31, 2025 | 688,000.00 |
| Dec 31, 2024 | 688,000.00 |
| Sep 30, 2024 | 688,000.00 |
| Jun 30, 2024 | 688,000.00 |
| Mar 31, 2024 | 897,000.00 |
| Dec 31, 2023 | 688,000.00 |
| Sep 30, 2023 | 426,000.00 |
| Jun 30, 2023 | 405,000.00 |
| Mar 31, 2023 | 416,000.00 |
| Dec 31, 2022 | 827,000.00 |
| Sep 30, 2022 | 846,000.00 |
| Jun 30, 2022 | 866,000.00 |
| Mar 31, 2022 | 904,000.00 |
| Dec 31, 2021 | 549,000.00 |
| Sep 30, 2021 | 925,000.00 |